Moody's downgrades AMN Healthcare's rating, negative outlook projected

Moody's downgraded AMN Healthcare's corporate family rating to Ba3 from Ba2, citing deteriorating credit metrics driven by declining revenue and compressed bill-pay spreads in the nurse staffing industry, leading to a debt-to-EBITDA ratio of 3.8x and expected to rise further. Despite cost-cutting measures and strong liquidity, the negative outlook reflects concerns that financial leverage will remain elevated, with potential for further downgrades if debt/EBITDA exceeds 4.25x or if the company adopts a more aggressive financial policy.

Analysis

Moody's has downgraded AMN Healthcare's Corporate Family Rating to Ba3 from Ba2 and its senior unsecured notes to B1 from Ba3, concurrently revising the company's outlook to negative from stable. This action primarily reflects AMN's deteriorating credit metrics, driven by a structural decline in revenue within the nurse staffing industry and ongoing compression of its bill-pay spread. Consequently, the company's debt-to-EBITDA ratio reached 3.8x for the last twelve months ending March 31, 2025, and Moody's projects this leverage will increase through the end of 2025 and remain above 4.0x for the subsequent 12-18 months. Although AMN has initiated cost-cutting measures, including workforce reductions, these have proven insufficient to fully counteract margin erosion and the decline in demand. Despite these challenges, AMN maintains a leading position in the temporary healthcare staffing market, an unchanged SGL-1 speculative grade liquidity rating (indicating very good liquidity), $56 million in cash reserves, and approximately $580 million available under its $750 million revolving credit facility expiring in February 2028. The company is also anticipated to generate between $100-$125 million in free cash flow over the next 12 months. However, the Ba3 rating is constrained by AMN's business model sensitivity to external factors such as high inflation, shortages of healthcare professionals, defensive strategies by key customers, and potential regulatory actions aimed at curbing healthcare expenses, alongside the expectation of persistently elevated financial leverage.

Key Decisions for Investors

• Given Moody's downgrade and the negative outlook stemming from rising leverage and declining revenues, investors should exercise significant caution regarding AMN Healthcare's debt and equity securities.
• Closely monitor AMN's debt-to-EBITDA ratio, as a sustained increase above 4.25x could trigger further rating downgrades, while also scrutinizing the effectiveness of cost-reduction strategies in stabilizing margins against persistent industry headwinds and demand normalization.
• While AMN's strong liquidity position and projected free cash flow offer some downside protection, the elevated risk profile warrants a thorough evaluation of exposure, considering potential adjustments or increased vigilance for signs of revenue stabilization or further deterioration in credit metrics.